IBIO Stock Price: iBio Inc. edges slightly lower after three consecutive days of big gains

NYSEAMERICAN:IBIO falls by 0.50% on Thursday after three straight days of gains at the start of the week.
iBIO has finally decided on IBIO-201 as its coronavirus vaccine of choice.
The entire COVID-19 biotech industry gained this week after AstraZeneca’s leading vaccine trial was halted.

Stocks Reporter FXStreet

NYSEAMERICAN:IBIO finally fell on Thursday alongside broader markets as the fallout from AstraZeneca halting its coronavirus vaccine study finally levelled off. iBIO has been a popular biotech penny stock amongst bargain investors that are targeting these micro-cap firms as potential industry disruptors. The stock has performed admirably thus far this year up 212.50% during the past 52-weeks – although shares are down over 70% from its 52-week highs of $7.45.

IBIO is more than just a coronavirus vaccine candidate though and investors know that the New York-based company has some more aces up its sleeve. Even if IBIO-201 is not chosen as the one the vaccines used to combat COVID-19, iBIO Inc. is well-positioned to be a global manufacturer of vaccine components with its FastPharming facility located in Bryan, Texas. The world is going to need upwards of 7 billion vaccines at some point and it may inevitably be a combination of biotech firms that band together to conquer the novel coronavirus.

IBIO Stock News

iBIO also has its hands in other sectors as it is developing IBIO-100 as well, which is a fusion protein for the treatment of fibrotic diseases. The recent selloff leading up to the AstraZeneca news has battered the stock down to levels where bargain investors should once again take notice. The race for the COVID-19 vaccine is wide open as other firms continue to fail and other companies have the chance to step up to the plate. While ultimately IBIO may not be the vaccine that is chosen, it certainly has a chance of carving out a role in the manufacturing of vaccines for global use.

Author

Stocks Reporter

FXStreet

GBP/USD flirts with tops near 1.3470

GBP/USD manages to regain composure and challenge the area of daily highs around 1.3470 on Friday. Cable picks up pace despite marginal gains in the Greenback in a context of swelling geopolitical tensions and rising global oil prices.

EUR/USD trims losses, back above 1.1500

EUR/USD picks up some pace and bouces off earlier lows, reclaiming the 1.1500 threshold and beyond at the end of the week. The pair’s modest pullback follows a persistent risk-averse market mood and renewed buying interest for the US Dollar.

Gold: The $4,000 mark holds the downside for now

Gold faces renewed selling pressure, falling sharply toweard the $4,000 mark per troy ounce as the US Dollar regains momentum. Escalating US-Iran tensions are keeping inflation concerns and expectations of further Fed rate hikes alive, weighing further on the yellow metal.

Bitcoin eyes 50-day EMA breakout, Ethereum consolidates, XRP steadies

Bitcoin, Ethereum, and Ripple trade near key technical levels on Friday as the broader cryptocurrency market pauses following last week's recovery. BTC is approaching the 50-day Exponential Moving Average while ETH continues to consolidate between two major EMAs.

Warsh needs to restore his reputation

We were glad to see our deeply negative reaction to the Warsh press conference was not some personal peculiarity. Just about everybody in the financial press felt the same way. The consensus is building it’s not the Fed in the dog-house but only Warsh. Today the WSJ changed it tune and blasted Warsh—"the honeymoon is already over..”

9-3: Is the Federal Reserve’s vote tally Warsh's new forward guidance?

The rate did not move. Neither did the statement, and that’s the more interesting fact. Set the July 29 Federal Open Market Committee (FOMC) statement beside the one issued on June 17, and the two documents are identical apart from a single verb and a paragraph at the bottom naming three dissenters.